1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Digital Technologies

Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA

 
• By Michael Cipriano

But sponsors should sometimes seek advisory comment. Agency explains that most drug-use-related apps will be considered promotional labeling. FDA seeking feedback from a variety of stakeholders on its discussion proposal for regulating prescription-focused software.

Touch the future,Interface technology, the future of user experience.

The US FDA anticipates that sponsors will generally not need to obtain pre-market approval for the output of prescription drug-use-related software, although the agency is also encouraging they use the voluntary advisory comment process in certain cases.

In officially announcing its discussion proposal in a Federal Registernotice scheduled to be published Nov

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

What India’s Digital Personal Data Protection Norms May Mean For Clinical Trials, Big Pharma GCCs

 
• By Anju Ghangurde

Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader talk about compliance requirements that pharma and global capability centers may need to consider as India strengthens the framework for the protection of digital personal data.

US FDA Acting Commissioner Pick Could Underscore Trump Team’s IT Focus

 
• By Ramsey Baghdadi

Sara Brenner has been a key figure in the FDA’s diagnostics team, but her choice as acting FDA commissioner likely has more to do with her background with advanced technology and comfort level with the tech-focused side of the Trump transition team.

How Pharma Can Prepare For Incoming EU Health Data Sharing Rules

 
• By Eliza Slawther

The Council of the EU has formally adopted the European Health Data Space regulation, meaning that it will soon enter into force in the EU. Experts explain what this means for the pharmaceutical industry.

‘Ambitious Platform’ Among EU Proposals For Increasing mHealth Data Use In Regulatory Decision-Making

 
• By Neena Brizmohun

mHealth data generated by smartphones and wearables show potential for enhancing the clinical evidence used in regulatory decision-making, but there are “notable challenges” that may hinder the use of such data, EU regulators say.

More from Advanced Technologies